Drug Trial Radar · NCT07110571
A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Aug 28, 2025
Primary completion
Aug 2026
Study completion May 2027
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-cohort, multi-center Phase II clinical study exploring the efficacy of treatment with either Adebrelimab plus SHR-A1811/SHR-A1904 and chemotherapy, or Adebrelimab plus SHR-8068 in patients with gastric or gastroesophageal junction (GEJ) cancer. The study also evaluates the safety and tolerability of these combination regimens.
Conditions
- Gastric Cancer
- Gastroesophageal-junction Cancer
Interventions
Adebrelimab InjectionDrug
Adebrelimab injection.
SHR-A1811 for InjectionDrug
SHR-A1811 for injection.
SHR-A1904 for InjectionDrug
SHR-A1904 for injection.
SHR-8068 InjectionDrug
SHR-8068 injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological complete response (pCR) rate assessed by the Pathology Review Committee (PRC).Time frame: Approximately 13 weeks.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.